Acute Myeloid Leukemia Aml clinical trials

Explore recruiting acute myeloid leukemia aml clinical trials.

Recruiting acute myeloid leukemia aml studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Myeloid Leukemia Aml trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of MK‑0482 in Participants with Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.

Greece, Italy, Germany, Spain, France, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

Czechia, Netherlands, France, Denmark, Spain, Portugal +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Spain, France, Germany, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Preemptive treatment with venetoclax plus azacitidine in patients diagnosed with acute myeloid leukemia (AML) with persistence or reappearance of measurable residual disease (MRD) after frontline chemotherapy and high-level MRD prior to allogeneic hematopoietic cell transplantation (alloHCT)

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Acute Myeloid Leukemia Aml trials by city

Acute Myeloid Leukemia Aml in Toronto Acute Myeloid Leukemia Aml in Vancouver Acute Myeloid Leukemia Aml in Montreal Acute Myeloid Leukemia Aml in Calgary Acute Myeloid Leukemia Aml in Edmonton Acute Myeloid Leukemia Aml in Ottawa Acute Myeloid Leukemia Aml in Winnipeg Acute Myeloid Leukemia Aml in Quebec City Acute Myeloid Leukemia Aml in Hamilton Acute Myeloid Leukemia Aml in Kitchener Acute Myeloid Leukemia Aml in London Acute Myeloid Leukemia Aml in Halifax Acute Myeloid Leukemia Aml in New York Acute Myeloid Leukemia Aml in Los Angeles Acute Myeloid Leukemia Aml in Chicago Acute Myeloid Leukemia Aml in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease